文献速递心外重症与机械循环支持

连续流外部心室辅助装置治疗心源性休克:10年演变

A continuous-flow external ventricular assist device for cardiogenic shock: Evolution over 10 years.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-02-13

单中心回顾性研究纳入2007年1月至2016年12月252例连续流外部心室辅助装置(VAD)植入患者,分为2007-2011年(Era 1,n=127)和2012-2016年(Era 2,n=125)两组。Era 2较Era 1术前经皮机械循环支持使用率更高(53% vs 23%,P<.01)、微创VAD配置更多(23% vs 6.7%,P<.01),住院死亡率更优(50% vs 37%,P=.04),1年总生存率更高(57% vs 43%,P=.04)。

要点

  • Era 2较Era 1术前经皮机械循环支持使用率更高(53% vs 23%,P<.01)。
  • Era 2较Era 1微创VAD配置使用更多(23% vs 6.7%,P<.01)。
  • Era 2住院死亡率50% vs Era 1 37%(P=.04),1年生存率57% vs 43%(P=.04)。

核心结论

  • 近期时代更好的结局可能与连续流外部VAD治疗难治性心源性休克的实践模式变化相关。

研究设计与样本

  • 单中心回顾性研究,纳入2007年1月至2016年12月252例连续流外部VAD植入患者,分为2007-2011年(Era 1,n=127)和2012-2016年(Era 2,n=125)两组,比较早期和晚期结局。

主要发现

  • Era 2较Era 1术前经皮机械循环支持使用率更高(53% vs 23%,P<.01)。
  • Era 2较Era 1微创VAD配置使用更多(23% vs 6.7%,P<.01)。
  • 桥接至下一目的地(包括心肌恢复、移植和耐久VAD)的比例两组相似。
  • Era 2住院死亡率50% vs Era 1 37%(P=.04),Era 2较Era 1降低。
  • Era 2 1年总生存率57% vs Era 1 43%(P=.04),Era 2较Era 1升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of percutaneous mechanical circulatory support (MCS) in the treatment of cardiogenic shock has increased. However, limitations in flow capability, ventricular unloading effect, durability, and mobility remain. We reviewed our single-center experience with continuous-flow external ventricular assist devices (VADs) to determine the role of temporary VADs for cardiogenic shock in the contemporary MCS era. METHODS: We retrospectively reviewed 252 patients who underwent continuous-flow external VAD insertion between January 2007 and December 2016. To investigate the change in indications, device configurations, and outcomes, we divided the cohort into 2 groups-2007 to 2011 (Era 1; n = 127) and 2012 to 2016 (Era 2; n = 125)-and compared early and late outcomes. RESULTS: Indications and device configurations changed significantly over time. The use of preoperative percutaneous MCS (53% vs 23%; P < .01) and use of minimally invasive VAD configurations (23% vs 6.7%; P < .01) were greater in Era 2 compared with Era 1. The rate of bridge to the next destinations, including myocardial recovery, transplantation, and durable VAD, was similar in the 2 groups. In-hospital mortality was significantly better in Era 2 (50% vs 37%; P = .04). Overall survival at 1 year was 57% in Era 2 versus 43% in Era 1 (P = .04). CONCLUSIONS: Better outcomes in the recent era could be associated with the changes in practice patterns using continuous-flow external VAD in patients with refractory cardiogenic shock.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ando M, Garan AR, Takayama H, et al. A continuous-flow external ventricular assist device for cardiogenic shock: Evolution over 10 years. J Thorac Cardiovasc Surg. 2018. PMID: 29510941. doi:10.1016/j.jtcvs.2017.12.148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。